AR and prostate cancer: The results presented in this study show that calcium activates the androgen receptor in nontumorigenic and tumorigenic prostate cells, second-generation antiandrogens are more effective than first-generation antiandrogens in blocking calcium activation of AR, and calcium channels are overexpressed in hormone-dependent and hormone-resistant prostate cancer cells.